Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Buck

Showing results (261-270 of 400) with videos related to

Pageof 40
Sort By:
Clinical Nuclear Medicine|November 8, 2016
Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer PatientsChristina Bluemel, Stefanie Hahner, Britta Heinze, et al.
Molecular Imaging and Biology|November 9, 2018
Impact of Tumor Burden on Quantitative [<sup>68</sup>Ga] DOTATOC BiodistributionRudolf A Werner, Heribert Hänscheid, Jeffrey P Leal, et al.
Oncotarget|December 13, 2017
Targeting CXCR4 with [<sup>68</sup>Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?Constantin Lapa, Stefan Kircher, Andreas Schirbel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2007
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanomaFelix M Mottaghy, Cord Sunderkötter, Roland Schubert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2008
In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumorsKen Herrmann, Florian Eckel, Stefan Schmidt, et al.
Cancers|February 15, 2022
Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [<sup>177</sup>Lu]Lu-PSMA I&TPhilipp E Hartrampf, Franz-Xaver Weinzierl, Sebastian E Serfling, et al.
Nuclear Medicine Communications|July 26, 2019
Impact of aging on semiquantitative uptake parameters in normal rated clinical baseline [123I]Ioflupane single photon emission computed tomography/computed tomographyRudolf A Werner, Constantin Lapa, Sara Sheikhbahaei, et al.
Biology|May 28, 2022
Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole ApproachPhilipp E Hartrampf, Markus Krebs, Lea Peter, et al.
Clinical Nuclear Medicine|April 7, 2021
Peptide Receptor Radionuclide Therapy in Patients With Neurofibromatosis Type 2: Initial ExperienceOlivia Kertels, Maria Breun, Heribert Hänscheid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 18, 2008
First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidineAndreas K Buck, Martin Bommer, Malik E Juweid, et al.
Pageof 40

Showing results (261-270 of 400) with videos related to

Sort By:
Pageof 40
Clinical Nuclear Medicine|November 8, 2016
Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer PatientsChristina Bluemel, Stefanie Hahner, Britta Heinze, et al.
Molecular Imaging and Biology|November 9, 2018
Impact of Tumor Burden on Quantitative [<sup>68</sup>Ga] DOTATOC BiodistributionRudolf A Werner, Heribert Hänscheid, Jeffrey P Leal, et al.
Oncotarget|December 13, 2017
Targeting CXCR4 with [<sup>68</sup>Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?Constantin Lapa, Stefan Kircher, Andreas Schirbel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2007
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanomaFelix M Mottaghy, Cord Sunderkötter, Roland Schubert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2008
In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumorsKen Herrmann, Florian Eckel, Stefan Schmidt, et al.
Cancers|February 15, 2022
Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [<sup>177</sup>Lu]Lu-PSMA I&TPhilipp E Hartrampf, Franz-Xaver Weinzierl, Sebastian E Serfling, et al.
Nuclear Medicine Communications|July 26, 2019
Impact of aging on semiquantitative uptake parameters in normal rated clinical baseline [123I]Ioflupane single photon emission computed tomography/computed tomographyRudolf A Werner, Constantin Lapa, Sara Sheikhbahaei, et al.
Biology|May 28, 2022
Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole ApproachPhilipp E Hartrampf, Markus Krebs, Lea Peter, et al.
Clinical Nuclear Medicine|April 7, 2021
Peptide Receptor Radionuclide Therapy in Patients With Neurofibromatosis Type 2: Initial ExperienceOlivia Kertels, Maria Breun, Heribert Hänscheid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 18, 2008
First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidineAndreas K Buck, Martin Bommer, Malik E Juweid, et al.
Pageof 40